|
US20110092677A1
(en)
*
|
2001-08-30 |
2011-04-21 |
Biorexis Technology, Inc. |
Modified transferin-antibody fusion proteins
|
|
TWI312285B
(en)
|
2001-10-25 |
2009-07-21 |
Depomed Inc |
Methods of treatment using a gastric retained gabapentin dosage
|
|
US7612112B2
(en)
|
2001-10-25 |
2009-11-03 |
Depomed, Inc. |
Methods of treatment using a gastric retained gabapentin dosage
|
|
US20030091630A1
(en)
*
|
2001-10-25 |
2003-05-15 |
Jenny Louie-Helm |
Formulation of an erodible, gastric retentive oral dosage form using in vitro disintegration test data
|
|
US20030152622A1
(en)
*
|
2001-10-25 |
2003-08-14 |
Jenny Louie-Helm |
Formulation of an erodible, gastric retentive oral diuretic
|
|
US7776314B2
(en)
|
2002-06-17 |
2010-08-17 |
Grunenthal Gmbh |
Abuse-proofed dosage system
|
|
KR20050111318A
(ko)
|
2003-01-13 |
2005-11-24 |
다이노젠 파마세우티컬스, 인코포레이티드 |
기능성 장 질환을 치료하는 방법
|
|
PL1638529T3
(pl)
*
|
2003-06-16 |
2017-03-31 |
Andrx Pharmaceuticals, Llc. |
Kompozycja doustna o przedłużonym uwalnianiu
|
|
US20070048228A1
(en)
|
2003-08-06 |
2007-03-01 |
Elisabeth Arkenau-Maric |
Abuse-proofed dosage form
|
|
US8075872B2
(en)
|
2003-08-06 |
2011-12-13 |
Gruenenthal Gmbh |
Abuse-proofed dosage form
|
|
DE10336400A1
(de)
|
2003-08-06 |
2005-03-24 |
Grünenthal GmbH |
Gegen Missbrauch gesicherte Darreichungsform
|
|
DE102004032051A1
(de)
|
2004-07-01 |
2006-01-19 |
Grünenthal GmbH |
Verfahren zur Herstellung einer gegen Missbrauch gesicherten, festen Darreichungsform
|
|
DE102005005446A1
(de)
|
2005-02-04 |
2006-08-10 |
Grünenthal GmbH |
Bruchfeste Darreichungsformen mit retardierter Freisetzung
|
|
DE10361596A1
(de)
|
2003-12-24 |
2005-09-29 |
Grünenthal GmbH |
Verfahren zur Herstellung einer gegen Missbrauch gesicherten Darreichungsform
|
|
JP2005132803A
(ja)
*
|
2003-10-31 |
2005-05-26 |
Ono Pharmaceut Co Ltd |
胃内滞留固形剤
|
|
US7201920B2
(en)
|
2003-11-26 |
2007-04-10 |
Acura Pharmaceuticals, Inc. |
Methods and compositions for deterring abuse of opioid containing dosage forms
|
|
JP2007513975A
(ja)
*
|
2003-12-12 |
2007-05-31 |
ペンウェスト ファーマシューティカルズ カンパニー |
徐放性トルセミド剤形
|
|
CA2550983C
(en)
*
|
2003-12-24 |
2013-09-17 |
Advancis Pharmaceutical Corporation |
Enhanced absorption of modified release dosage forms
|
|
EP1731139A4
(en)
*
|
2004-03-31 |
2008-12-03 |
Aspion Co Ltd |
PHARMACEUTICAL PREPARATION OF THE S / O TYPE AND MANUFACTURING METHOD THEREFOR
|
|
CA2561700A1
(en)
*
|
2004-04-16 |
2005-12-15 |
Santarus, Inc. |
Combination of proton pump inhibitor, buffering agent, and prokinetic agent
|
|
DE102004032049A1
(de)
|
2004-07-01 |
2006-01-19 |
Grünenthal GmbH |
Gegen Missbrauch gesicherte, orale Darreichungsform
|
|
JP5175553B2
(ja)
*
|
2005-02-01 |
2013-04-03 |
エミスフェアー・テクノロジーズ・インク |
胃内滞留および制御放出型送達系
|
|
DE102005005449A1
(de)
|
2005-02-04 |
2006-08-10 |
Grünenthal GmbH |
Verfahren zur Herstellung einer gegen Missbrauch gesicherten Darreichungsform
|
|
EP1690540A1
(en)
*
|
2005-02-15 |
2006-08-16 |
Neuro3D |
Composition comprising ocaperidone
|
|
US20090214640A1
(en)
*
|
2005-03-04 |
2009-08-27 |
Intelgenx Cporp. |
Delayed release pharmaceutical oral dosage form and method of making same
|
|
US7919483B2
(en)
*
|
2005-06-24 |
2011-04-05 |
Medicis Pharmaceutical Corporation |
Method for the treatment of acne
|
|
US20080242642A1
(en)
|
2007-04-02 |
2008-10-02 |
Medicis Pharmaceutical Corporation |
Minocycline oral dosage forms for the treatment of acne
|
|
US9192615B2
(en)
|
2008-08-06 |
2015-11-24 |
Medicis Pharmaceutical Corporation |
Method for the treatment of acne and certain dosage forms thereof
|
|
US8252776B2
(en)
*
|
2007-04-02 |
2012-08-28 |
Medicis Pharmaceutical Corporation |
Minocycline oral dosage forms for the treatment of acne
|
|
US8722650B1
(en)
|
2005-06-24 |
2014-05-13 |
Medicis Pharmaceutical Corporation |
Extended-release minocycline dosage forms
|
|
AU2006329564A1
(en)
|
2005-07-11 |
2007-07-05 |
Pharmena North America Inc. |
Formulations for treatment of lipoprotein abnormalities comprising a statin a statin and a methylnicotinamide derivative
|
|
US8497258B2
(en)
|
2005-11-12 |
2013-07-30 |
The Regents Of The University Of California |
Viscous budesonide for the treatment of inflammatory diseases of the gastrointestinal tract
|
|
US20090176882A1
(en)
*
|
2008-12-09 |
2009-07-09 |
Depomed, Inc. |
Gastric retentive gabapentin dosage forms and methods for using same
|
|
SA07280459B1
(ar)
|
2006-08-25 |
2011-07-20 |
بيورديو فارما إل. بي. |
أشكال جرعة صيدلانية للتناول عن طريق الفم مقاومة للعبث تشتمل على مسكن شبه أفيوني
|
|
PE20080907A1
(es)
*
|
2006-08-31 |
2008-08-22 |
Novartis Ag |
Sistema de suministro de farmaco oral gastro-retentivo de liberacion extendida para valsartan
|
|
PE20080669A1
(es)
*
|
2006-09-08 |
2008-07-18 |
Drugtech Corp |
Composicion de liberacion sostenida que comprende levodopa
|
|
US8445018B2
(en)
|
2006-09-15 |
2013-05-21 |
Cima Labs Inc. |
Abuse resistant drug formulation
|
|
DE102007011485A1
(de)
|
2007-03-07 |
2008-09-11 |
Grünenthal GmbH |
Darreichungsform mit erschwertem Missbrauch
|
|
GB0707127D0
(en)
*
|
2007-04-13 |
2007-05-23 |
Zysis Ltd |
Pharmaceutical compositions
|
|
US8969514B2
(en)
|
2007-06-04 |
2015-03-03 |
Synergy Pharmaceuticals, Inc. |
Agonists of guanylate cyclase useful for the treatment of hypercholesterolemia, atherosclerosis, coronary heart disease, gallstone, obesity and other cardiovascular diseases
|
|
WO2008151257A2
(en)
|
2007-06-04 |
2008-12-11 |
Synergy Pharmaceuticals Inc. |
Agonists of guanylate cyclase useful for the treatment of gastrointestinal disorders, inflammation, cancer and other disorders
|
|
TW200914006A
(en)
*
|
2007-07-12 |
2009-04-01 |
Takeda Pharmaceutical |
Coated preparation
|
|
MX2010001071A
(es)
*
|
2007-07-27 |
2010-03-09 |
Depomed Inc |
Formas de dosificacion retentivas gastricas pulsatiles.
|
|
DK3354276T3
(da)
*
|
2007-11-13 |
2020-03-30 |
Meritage Pharma Inc |
Sammensætninger til behandlingen af gastrointestinal inflammation
|
|
US20090143343A1
(en)
|
2007-11-13 |
2009-06-04 |
Meritage Pharma, Inc. |
Compositions for the treatment of inflammation of the gastrointestinal tract
|
|
TWI454288B
(zh)
|
2008-01-25 |
2014-10-01 |
Gruenenthal Chemie |
藥物劑型
|
|
US8372432B2
(en)
|
2008-03-11 |
2013-02-12 |
Depomed, Inc. |
Gastric retentive extended-release dosage forms comprising combinations of a non-opioid analgesic and an opioid analgesic
|
|
ES2599031T3
(es)
|
2008-05-09 |
2017-01-31 |
Grünenthal GmbH |
Proceso para la preparación de una formulación de polvo intermedia y una forma de dosificación solida final utilizando un paso de congelación por pulverización
|
|
ES2627848T3
(es)
|
2008-06-04 |
2017-07-31 |
Synergy Pharmaceuticals Inc. |
Agonistas de la guanilato ciclasa útiles para el tratamiento de trastornos gastrointestinales, inflamación, cáncer y otros trastornos
|
|
ES2624828T3
(es)
|
2008-07-16 |
2017-07-17 |
Synergy Pharmaceuticals Inc. |
Agonistas de la guanilato ciclasa útiles para el tratamiento de trastornos gastrointestinales, inflamación, cáncer y otros
|
|
ES2740360T3
(es)
*
|
2008-08-15 |
2020-02-05 |
Assertio Therapeutics Inc |
Composiciones farmacéuticas de retención gástrica para el tratamiento y la prevención de trastornos del SNC
|
|
BRPI0914080A2
(pt)
|
2008-10-08 |
2015-10-27 |
Bioplus Life Sciences Pvt Ltda |
"sistema de liberação de dosagem controlada, método de administração e processo de preparação do mesmo"
|
|
US8815971B2
(en)
|
2008-12-22 |
2014-08-26 |
ATRP Solutions, Inc. |
Control over controlled radical polymerization processes
|
|
US8822610B2
(en)
|
2008-12-22 |
2014-09-02 |
ATRP Solutions, Inc. |
Control over controlled radical polymerization processes
|
|
EP2210585A1
(en)
|
2009-01-16 |
2010-07-28 |
Exelgyn |
SPRM pharmaceutical compositions methods of treatment using them
|
|
WO2010123574A1
(en)
|
2009-04-23 |
2010-10-28 |
Atrp Solutions Inc |
Star macromolecules for personal and home care
|
|
US8173750B2
(en)
|
2009-04-23 |
2012-05-08 |
ATRP Solutions, Inc. |
Star macromolecules for personal and home care
|
|
US9783628B2
(en)
|
2009-04-23 |
2017-10-10 |
ATRP Solutions, Inc. |
Dual-mechanism thickening agents for hydraulic fracturing fluids
|
|
EP2427243A4
(en)
|
2009-05-05 |
2012-11-21 |
Vapogenix Inc |
NEW FORMULATIONS OF VOLATILE ANESTHETICS AND METHOD OF ADMINISTRATION
|
|
ES2534908T3
(es)
|
2009-07-22 |
2015-04-30 |
Grünenthal GmbH |
Forma de dosificación de liberación controlada extruida por fusión en caliente
|
|
BR112012001466A2
(pt)
|
2009-07-22 |
2020-08-11 |
Grünenthal GmbH |
forma de dosagem resistente à falsificação para opioides sensíveis à oxidação, seu processo de fabricação, e embalagem
|
|
US8758323B2
(en)
|
2009-07-30 |
2014-06-24 |
Tandem Diabetes Care, Inc. |
Infusion pump system with disposable cartridge having pressure venting and pressure feedback
|
|
FR2949061B1
(fr)
*
|
2009-08-12 |
2013-04-19 |
Debregeas Et Associes Pharma |
Microgranules flottants
|
|
WO2011027346A1
(en)
*
|
2009-09-03 |
2011-03-10 |
Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd. |
A gastroretentive dosage form for oral treatment of domestic animals
|
|
EP3064064A1
(en)
|
2009-09-30 |
2016-09-07 |
Acura Pharmaceuticals, Inc. |
Methods and compositions for deterring abuse
|
|
US8597681B2
(en)
|
2009-12-22 |
2013-12-03 |
Mallinckrodt Llc |
Methods of producing stabilized solid dosage pharmaceutical compositions containing morphinans
|
|
US9198861B2
(en)
|
2009-12-22 |
2015-12-01 |
Mallinckrodt Llc |
Methods of producing stabilized solid dosage pharmaceutical compositions containing morphinans
|
|
US20110150989A1
(en)
*
|
2009-12-22 |
2011-06-23 |
Mallinkckrodt Inc. |
Methods of Producing Stabilized Solid Dosage Pharmaceutical Compositions Containing Morphinans
|
|
US9579285B2
(en)
|
2010-02-03 |
2017-02-28 |
Gruenenthal Gmbh |
Preparation of a powdery pharmaceutical composition by means of an extruder
|
|
JP6245983B2
(ja)
|
2010-08-11 |
2017-12-13 |
ドレクセル ユニバーシティ |
パーキンソン病におけるジスキネジアを治療するための新規ｄ３ドーパミン受容体アゴニスト
|
|
WO2012028318A1
(en)
|
2010-09-02 |
2012-03-08 |
Grünenthal GmbH |
Tamper resistant dosage form comprising an anionic polymer
|
|
CA2808219C
(en)
|
2010-09-02 |
2019-05-14 |
Gruenenthal Gmbh |
Tamper resistant dosage form comprising inorganic salt
|
|
US9616097B2
(en)
|
2010-09-15 |
2017-04-11 |
Synergy Pharmaceuticals, Inc. |
Formulations of guanylate cyclase C agonists and methods of use
|
|
EP2648754A4
(en)
|
2010-12-07 |
2016-02-24 |
Philadelphia Health & Educatio |
METHOD OF INHIBITING CANCER METASTASES
|
|
US9587064B2
(en)
|
2010-12-08 |
2017-03-07 |
ATRP Solutions, Inc. |
Salt-tolerant star macromolecules
|
|
US8476221B2
(en)
|
2011-03-18 |
2013-07-02 |
Halimed Pharmaceuticals, Inc. |
Methods and compositions for the treatment of metabolic disorders
|
|
US8741885B1
(en)
|
2011-05-17 |
2014-06-03 |
Mallinckrodt Llc |
Gastric retentive extended release pharmaceutical compositions
|
|
US9050335B1
(en)
|
2011-05-17 |
2015-06-09 |
Mallinckrodt Llc |
Pharmaceutical compositions for extended release of oxycodone and acetaminophen resulting in a quick onset and prolonged period of analgesia
|
|
US8858963B1
(en)
|
2011-05-17 |
2014-10-14 |
Mallinckrodt Llc |
Tamper resistant composition comprising hydrocodone and acetaminophen for rapid onset and extended duration of analgesia
|
|
US9561241B1
(en)
|
2011-06-28 |
2017-02-07 |
Medicis Pharmaceutical Corporation |
Gastroretentive dosage forms for minocycline
|
|
US9119793B1
(en)
|
2011-06-28 |
2015-09-01 |
Medicis Pharmaceutical Corporation |
Gastroretentive dosage forms for doxycycline
|
|
BR112014002022A2
(pt)
|
2011-07-29 |
2017-02-21 |
Gruenenthal Gmbh |
comprimido resistente à violação proporcionando liberação de fármaco imediata
|
|
JP6063462B2
(ja)
|
2011-07-29 |
2017-01-18 |
グリュネンタール・ゲゼルシャフト・ミト・ベシュレンクテル・ハフツング |
即時薬剤放出を提供するタンパーレジスタント錠剤
|
|
AU2012345659B2
(en)
|
2011-12-02 |
2017-09-28 |
Synchroneuron Inc. |
Acamprosate formulations, methods of using the same, and combinations comprising the same
|
|
EP2794565B1
(en)
|
2011-12-21 |
2017-07-26 |
Novira Therapeutics Inc. |
Hepatitis b antiviral agents
|
|
BR112014019988A8
(pt)
|
2012-02-28 |
2017-07-11 |
Gruenenthal Gmbh |
Forma de dosagem resistente a socamento compreendendo um composto farmacologicamente ativo e um polímero aniônico
|
|
CN102579344B
(zh)
*
|
2012-03-02 |
2014-02-26 |
海南美兰史克制药有限公司 |
氯沙坦钾脂质体固体制剂
|
|
LT2838512T
(lt)
|
2012-04-18 |
2018-11-12 |
GrĆ¼nenthal GmbH |
Pažeidimui atspari ir dozės atpalaidavimo nuokrypiui atspari farmacinė vaisto forma
|
|
US10064945B2
(en)
|
2012-05-11 |
2018-09-04 |
Gruenenthal Gmbh |
Thermoformed, tamper-resistant pharmaceutical dosage form containing zinc
|
|
US9180242B2
(en)
|
2012-05-17 |
2015-11-10 |
Tandem Diabetes Care, Inc. |
Methods and devices for multiple fluid transfer
|
|
US9730885B2
(en)
|
2012-07-12 |
2017-08-15 |
Mallinckrodt Llc |
Extended release, abuse deterrent pharmaceutical compositions
|
|
WO2014015157A2
(en)
|
2012-07-19 |
2014-01-23 |
Philadelphia Health & Education Corporation |
Novel sigma receptor ligands and methods of modulating cellular protein homeostasis using same
|
|
EP3158995B1
(en)
|
2012-08-09 |
2018-05-23 |
Dynamis Therapeutics, Inc. |
Meglumine for reducing high triglyceride levels
|
|
EP2890760A4
(en)
|
2012-08-30 |
2016-10-12 |
Atrp Solutions Inc |
DOUBLE MECHANISM THICKENERS FOR HYDRAULIC FRACKING FLUIDS
|
|
JP6362601B2
(ja)
|
2012-09-18 |
2018-07-25 |
オースペックス・ファーマシューティカルズ・インコーポレイテッドＡｕｓｐｅｘ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ， Ｉｎｃ． |
小胞モノアミン輸送体２の重水素化ベンゾキノリン阻害剤の製剤薬物動態
|
|
US9550780B2
(en)
|
2012-09-18 |
2017-01-24 |
Auspex Pharmaceuticals, Inc. |
Formulations pharmacokinetics of deuterated benzoquinoline inhibitors of vesicular monoamine transporter 2
|
|
CN104968333B
(zh)
|
2012-11-30 |
2018-07-10 |
阿库拉制药公司 |
活性药物成分的自调节释放
|
|
WO2014100077A1
(en)
*
|
2012-12-21 |
2014-06-26 |
Merck Sharp & Dohme Corp. |
Gastro-retentive formulations
|
|
PT2941233T
(pt)
|
2013-01-07 |
2020-11-13 |
Univ Pennsylvania |
Composições e métodos para tratar linfoma cutâneo de células t
|
|
EP2951220B1
(en)
|
2013-02-04 |
2020-11-25 |
Pilot Polymer Technologies, Inc. |
Salt-tolerant star macromolecules
|
|
EP2958577A2
(en)
|
2013-02-25 |
2015-12-30 |
Synergy Pharmaceuticals Inc. |
Guanylate cyclase receptor agonists for use in colonic cleansing
|
|
US10201656B2
(en)
|
2013-03-13 |
2019-02-12 |
Tandem Diabetes Care, Inc. |
Simplified insulin pump for type II diabetics
|
|
US9173998B2
(en)
|
2013-03-14 |
2015-11-03 |
Tandem Diabetes Care, Inc. |
System and method for detecting occlusions in an infusion pump
|
|
US10842802B2
(en)
|
2013-03-15 |
2020-11-24 |
Medicis Pharmaceutical Corporation |
Controlled release pharmaceutical dosage forms
|
|
US9708367B2
(en)
|
2013-03-15 |
2017-07-18 |
Synergy Pharmaceuticals, Inc. |
Agonists of guanylate cyclase and their uses
|
|
EP2968439A2
(en)
|
2013-03-15 |
2016-01-20 |
Synergy Pharmaceuticals Inc. |
Compositions useful for the treatment of gastrointestinal disorders
|
|
US9492608B2
(en)
|
2013-03-15 |
2016-11-15 |
Tandem Diabetes Care, Inc. |
Method and device utilizing insulin delivery protocols
|
|
AU2014273227B2
(en)
|
2013-05-29 |
2019-08-15 |
Grunenthal Gmbh |
Tamper-resistant dosage form containing one or more particles
|
|
MX2015016254A
(es)
|
2013-05-29 |
2016-04-20 |
Gruenenthal Gmbh |
Forma de dosificacion resistente al uso indebido con perfil de liberacion bimodal.
|
|
WO2014197744A1
(en)
|
2013-06-05 |
2014-12-11 |
Synchroneuron, Inc. |
Acamprosate formulations, methods of using the same, and combinations comprising the same
|
|
US10117841B2
(en)
|
2013-07-02 |
2018-11-06 |
Ecoplanet Environmental Llc |
Volatile organic compound formulations having antimicrobial activity
|
|
GB201311888D0
(en)
|
2013-07-03 |
2013-08-14 |
Glaxosmithkline Ip Dev Ltd |
Novel compounds
|
|
GB201311891D0
(en)
|
2013-07-03 |
2013-08-14 |
Glaxosmithkline Ip Dev Ltd |
Novel compound
|
|
AU2014289187B2
(en)
|
2013-07-12 |
2019-07-11 |
Grunenthal Gmbh |
Tamper-resistant dosage form containing ethylene-vinyl acetate polymer
|
|
CA2926691A1
(en)
|
2013-10-10 |
2015-04-16 |
Synergy Pharmaceuticals, Inc. |
Agonists of guanylate cyclase useful for the treatment of opioid induced dysfunctions
|
|
US9908915B2
(en)
|
2013-11-26 |
2018-03-06 |
Yale University |
Cell-penetrating compositions and methods using same
|
|
HK1224189A1
(zh)
|
2013-11-26 |
2017-08-18 |
Grünenthal GmbH |
通过低温研磨制备粉状药物组合物
|
|
AU2014357518A1
(en)
|
2013-12-03 |
2016-06-09 |
Auspex Pharmaceuticals, Inc. |
Methods of manufacturing benzoquinoline compounds
|
|
WO2015089049A1
(en)
|
2013-12-09 |
2015-06-18 |
Thomas Jefferson University |
Novel methods of treating a neurodegenerative disease in a mammal in need thereof
|
|
WO2015157262A1
(en)
|
2014-04-07 |
2015-10-15 |
Women & Infants Hospital Of Rhode Island |
Novel 7-Dehydrocholesterol Derivatives and Methods Using Same
|
|
US20180228907A1
(en)
|
2014-04-14 |
2018-08-16 |
Arvinas, Inc. |
Cereblon ligands and bifunctional compounds comprising the same
|
|
WO2015173195A1
(en)
|
2014-05-12 |
2015-11-19 |
Grünenthal GmbH |
Tamper resistant immediate release capsule formulation comprising tapentadol
|
|
US9872835B2
(en)
|
2014-05-26 |
2018-01-23 |
Grünenthal GmbH |
Multiparticles safeguarded against ethanolic dose-dumping
|
|
US10485758B2
(en)
|
2014-06-02 |
2019-11-26 |
Clexio Biosciences Ltd. |
Expandable gastroretentive dosage form
|
|
MX2016016406A
(es)
*
|
2014-06-11 |
2017-10-12 |
Massachusetts Inst Technology |
Estructuras de permanencia, y métodos relacionados.
|
|
MX385886B
(es)
|
2014-07-03 |
2025-03-18 |
Pilot Polymer Tech Inc |
Macromoleculas estrellas compatibles con tensoactivos.
|
|
CA2968215A1
(en)
|
2014-08-20 |
2016-02-25 |
Yale University |
Novel compositions and methods useful for treating or preventing liver diseases or disorders, and promoting weight loss
|
|
PL3265085T3
(pl)
|
2015-03-06 |
2022-11-07 |
Auspex Pharmaceuticals, Inc. |
Sposoby leczenia zaburzeń związanych z nieprawidłowymi ruchami mimowolnymi
|
|
WO2016170097A1
(en)
|
2015-04-24 |
2016-10-27 |
Grünenthal GmbH |
Tamper-resistant dosage form with immediate release and resistance against solvent extraction
|
|
US10597368B2
(en)
|
2015-05-08 |
2020-03-24 |
Brown University |
Syringolin analogues and methods of making and using same
|
|
EP3298140B1
(en)
|
2015-05-19 |
2024-04-24 |
Yale University |
Compositions for treating pathological calcification conditions, and methods using same
|
|
EP3302442B1
(en)
|
2015-06-03 |
2024-10-16 |
Triastek, Inc. |
Dosage forms and use thereof
|
|
US10829440B2
(en)
|
2015-06-12 |
2020-11-10 |
Brown University |
Antibacterial compounds and methods of making and using same
|
|
CA2989885C
(en)
|
2015-06-30 |
2025-05-06 |
Neurad Ltd. |
NEW RESPIRATION REGULATION MODULATION COMPOUNDS AND THEIR MANUFACTURING AND USE PROCESSES
|
|
US11090354B2
(en)
|
2015-08-06 |
2021-08-17 |
The Johns Hopkins University |
Composition and method for treatment of metabolic disorders
|
|
WO2017040607A1
(en)
|
2015-08-31 |
2017-03-09 |
Acura Pharmaceuticals, Inc. |
Methods and compositions for self-regulated release of active pharmaceutical ingredient
|
|
CA2998259A1
(en)
|
2015-09-10 |
2017-03-16 |
Grunenthal Gmbh |
Protecting oral overdose with abuse deterrent immediate release formulations
|
|
WO2017075145A1
(en)
|
2015-10-28 |
2017-05-04 |
Yale University |
Quinoline amides and methods of using same
|
|
EP3377105A4
(en)
|
2015-11-20 |
2019-04-24 |
Yale University |
COMPOSITIONS FOR THE TREATMENT OF ECTOPIC CALIBRATION DISORDERS AND METHODS THEREWITH
|
|
EP3402804A1
(en)
|
2016-01-11 |
2018-11-21 |
Synergy Pharmaceuticals Inc. |
Formulations and methods for treating ulcerative colitis
|
|
EP3448369B1
(en)
|
2016-04-29 |
2025-06-25 |
The Regents of The University of Colorado, A Body Corporate |
Inhibition or degradation of hdac11 for treating obesity, hyperlipidemia, type ii diabetes, metabolic syndrome or insulin resistance, for promoting weight loss, and/or ameliorating or preventing weight gain
|
|
US20210330599A1
(en)
|
2016-08-01 |
2021-10-28 |
University Of Rochester |
Nanoparticles for Controlled Release of Anti-Biofilm Agents and Methods of Use
|
|
US11390859B2
(en)
|
2016-08-05 |
2022-07-19 |
Yale University |
Compositions and methods for stroke prevention in pediatric sickle cell anemia patients
|
|
EP3506983B1
(en)
|
2016-09-01 |
2021-08-25 |
Mebias Discovery, Inc. |
Substituted urea-derivatives for the treatment of pain
|
|
JP7113009B2
(ja)
|
2016-11-07 |
2022-08-04 |
アービュタス バイオファーマ コーポレイション |
置換ピリジノン含有三環式化合物およびそれを使用する方法
|
|
ES2966736T3
(es)
|
2016-12-02 |
2024-04-24 |
Clexio Biosciences Ltd |
Sistema de residencia gástrica
|
|
US10941126B2
(en)
|
2017-01-19 |
2021-03-09 |
Temple University-Of The Commonwealth System Of Higher Education |
Bridged bicycloalkyl-substituted aminothiazoles and their methods of use
|
|
MA49014A
(fr)
|
2017-03-21 |
2020-02-05 |
Arbutus Biopharma Corp |
Dihydroindène-4-carboxamides substitués, leurs analogues et procédés d'utilisation correspondant
|
|
CN110753546B
(zh)
|
2017-04-17 |
2023-11-10 |
耶鲁大学 |
治疗或预防急性肺损伤的化合物、组合物和方法
|
|
US10588863B2
(en)
|
2017-06-16 |
2020-03-17 |
Kashiv Biosciences, Llc |
Extended release compositions comprising pyridostigmine
|
|
WO2018232413A1
(en)
|
2017-06-16 |
2018-12-20 |
Kashiv Pharma Llc |
Gastroretentive dosage forms for sustained drug delivery
|
|
US10987311B2
(en)
|
2017-06-16 |
2021-04-27 |
Kashiv Specialty Pharmaceuticals, Llc |
Extended release compositions comprising pyridostigmine
|
|
CA3071345A1
(en)
|
2017-07-28 |
2019-01-31 |
Yale University |
Anticancer drugs and methods of making and using same
|
|
CN111527103A
(zh)
|
2017-09-08 |
2020-08-11 |
科罗拉多大学董事会,法人团体 |
用于治疗或预防her驱动的抗药性癌症的化合物、组合物和方法
|
|
EP3706720B1
(en)
*
|
2017-11-07 |
2026-07-01 |
Rani Therapeutics, LLC |
COAGULATION FACTOR PREPARATIONS FOR ADMINISTERING INTO INTESTINAL TRACT TISSUE BY MEANS OF AN ORGIVE-IN-SWALLOW MEDICATION DELIVERY DEVICE
|
|
WO2019104316A1
(en)
|
2017-11-27 |
2019-05-31 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Compounds, compositions, and methods for treating and/or preventing periodontal disease
|
|
WO2019111132A1
(en)
|
2017-12-04 |
2019-06-13 |
Clexio Biosciences Ltd. |
Long acting gastric residence system
|
|
US12514818B2
(en)
|
2017-12-18 |
2026-01-06 |
Tris Pharma, Inc. |
Pharmaceutical compositions comprising a floating interpenetrating polymer network forming system
|
|
AU2018388577B2
(en)
|
2017-12-18 |
2024-06-06 |
Tris Pharma, Inc. |
Modified release drug powder composition comprising gastro-retentive raft forming systems having trigger pulse drug release
|
|
US11666546B2
(en)
|
2017-12-18 |
2023-06-06 |
Tris Pharma, Inc |
GHB pharmaceutical compositions comprising a floating interpenetrating polymer network forming system
|
|
US11337920B2
(en)
|
2017-12-18 |
2022-05-24 |
Tris Pharma, Inc. |
Pharmaceutical composition comprising GHB gastro-retentive raft forming systems having trigger pulse drug release
|
|
WO2019125184A1
(en)
|
2017-12-19 |
2019-06-27 |
Auckland Uniservices Limited |
Use of biomarker in cancer therapy
|
|
US12161754B2
(en)
|
2017-12-20 |
2024-12-10 |
Purdue Pharma L.P. |
Abuse deterrent morphine sulfate dosage forms
|
|
AU2019212241A1
(en)
|
2018-01-24 |
2020-08-13 |
The Rockefeller University |
Antibacterial compounds, compositions thereof, and methods using same
|
|
ES2948788T3
(es)
|
2018-01-29 |
2023-09-19 |
Univ Duke |
Composiciones y métodos para mejorar la biodisponibilidad del 5-hidroxitriptófano
|
|
JP7572006B2
(ja)
|
2018-05-25 |
2024-10-23 |
テンプル ユニヴァーシティ － オブ ザ コモンウェルス システム オブ ハイアー エデュケーション |
抗アミロイドモノクローナル抗体を使用した細菌バイオフィルムの根絶
|
|
KR20210015892A
(ko)
|
2018-05-29 |
2021-02-10 |
세르시 테라퓨틱스 인코포레이티드 |
통증 치료를 위한 화합물, 이를 포함하는 조성물 및 이를 사용하는 방법
|
|
DK3609472T3
(da)
|
2018-06-18 |
2021-04-06 |
Kashiv Specialty Pharmaceuticals Llc |
Forlænget frigivelsessammensætning indeholdende pyridostigmin
|
|
TWI869058B
(zh)
|
2018-07-27 |
2025-01-01 |
加拿大商愛彼特生物製藥公司 |
經取代四氫環戊[c]吡咯、經取代二氫吡咯，其類似物及使用其之方法
|
|
CN112703009B
(zh)
|
2018-08-17 |
2024-06-11 |
宾夕法尼亚大学董事会 |
治疗急性肺损伤的组合物和方法
|
|
MX2021003653A
(es)
|
2018-10-11 |
2021-06-23 |
Sanifit Therapeutics S A |
Inositol fosfatos para el tratamiento de calcificacion ectopica.
|
|
US12458601B2
(en)
|
2018-10-19 |
2025-11-04 |
Temple University-Of The Commonwealth System Of Higher Education |
Tamper-resistant drug dosage forms and methods of making and use thereof
|
|
TWI827760B
(zh)
|
2018-12-12 |
2024-01-01 |
加拿大商愛彼特生物製藥公司 |
經取代之芳基甲基脲類及雜芳基甲基脲類、其類似物及其使用方法
|
|
WO2020157362A1
(en)
|
2019-01-30 |
2020-08-06 |
Sanifit Therapeutics, S.A. |
Inositol phosphate compounds for use in increasing tissular perfusion
|
|
US20200246317A1
(en)
|
2019-02-01 |
2020-08-06 |
Cersci Therapeutics, Inc. |
Methods of treating diabetic neuropathy with a thiazoline anti-hyperalgesic agent
|
|
WO2020159565A1
(en)
|
2019-02-01 |
2020-08-06 |
Cersci Therapeutics, Inc. |
Methods of treating post-surgical pain with a thiazoline anti-hyperalgesic agent
|
|
AU2020271901A1
(en)
|
2019-04-12 |
2021-11-04 |
Sdg, Inc. |
Lipid-based nanoparticles and use of same in optimized insulin dosing regimens
|
|
US11471508B2
(en)
|
2019-05-09 |
2022-10-18 |
The Feinstein Institutes For Medical Research |
HMGB1 antagonist treatment of diabetic peripheral neuropathy
|
|
EP3983391A4
(en)
|
2019-06-12 |
2023-06-28 |
The Wistar Institute |
Acetyl-coa synthetase 2 (acss2) inhibitors and methods using same
|
|
US11555010B2
(en)
|
2019-07-25 |
2023-01-17 |
Brown University |
Diamide antimicrobial agents
|
|
EP3818983A1
(en)
|
2019-11-11 |
2021-05-12 |
Sanifit Therapeutics S.A. |
Inositol phosphate compounds for use in treating, inhibiting the progression, or preventing cardiovascular calcification
|
|
WO2021127456A1
(en)
|
2019-12-19 |
2021-06-24 |
Rain Therapeutics Inc. |
Methods of inhibiting epidermal growth factor receptor proteins
|
|
EP4162036A1
(en)
|
2020-06-09 |
2023-04-12 |
Inozyme Pharma, Inc. |
Soluble enpp1 or enpp3 proteins and uses thereof
|
|
WO2022067165A1
(en)
|
2020-09-28 |
2022-03-31 |
Yale University |
Selective agonists of 5-ht2a receptor and methods of use
|
|
KR20230098220A
(ko)
*
|
2020-10-30 |
2023-07-03 |
트리아스텍 인코포레이티드 |
위 체류를 위한 약물 제형
|
|
EP4015494A1
(en)
|
2020-12-15 |
2022-06-22 |
Sanifit Therapeutics S.A. |
Processes for the preparation of soluble salts of inositol phosphates
|
|
EP4036097A1
(en)
|
2021-01-29 |
2022-08-03 |
Sanifit Therapeutics S.A. |
Ip4-4,6 substituted derivative compounds
|
|
WO2023004291A1
(en)
|
2021-07-19 |
2023-01-26 |
Baylor College Of Medicine |
Coronavirus main protease inhibitors and methods using same
|
|
AU2022320730A1
(en)
|
2021-07-30 |
2024-03-14 |
Evecxia Therapeutics, Inc. |
5-hydroxytryptophan gastroretentive dosage forms
|
|
US12409163B2
(en)
|
2021-07-30 |
2025-09-09 |
Evecxia Therapeutics, Inc. |
Method of enhancing 5-hydroxytryptophan (5-HTP) exposure
|
|
US11779567B2
(en)
|
2021-10-14 |
2023-10-10 |
Evecxia Therapeutics, Inc. |
Method for optimizing 5-hydroxytryptamine function in the brain for therapeutic purposes
|
|
TW202412815A
(zh)
|
2022-07-29 |
2024-04-01 |
西班牙商薩尼菲特治療公司 |
Ip5經取代化合物
|
|
AU2023313374A1
(en)
|
2022-07-29 |
2025-02-13 |
Vifor (International) Ltd. |
Ip4-4,6 substituted derivative compounds for use in the treatment, inhibition of progression, and prevention of ectopic calcification
|
|
CN115184371B
(zh)
*
|
2022-08-05 |
2023-04-25 |
深圳市俱进纸品包装有限公司 |
一种礼盒印刷的瑕疵视觉检测装置
|
|
WO2024052895A1
(en)
|
2022-09-06 |
2024-03-14 |
Hadasit Medical Research Services And Development Ltd |
Combinations comprising psychedelics for the treatment of schizophrenia and other neuropsychiatric and neurologic disorders
|
|
KR102910352B1
(ko)
*
|
2023-01-02 |
2026-01-09 |
일양약품주식회사 |
베타네콜을 함유하는 안정한 방출 제어형 약제학적 조성물 및 이의 제조방법
|
|
CN121038779A
(zh)
|
2023-02-03 |
2025-11-28 |
特瑞斯制药公司 |
每晚一次的低钠羟丁酸盐组合物
|
|
KR20260053367A
(ko)
|
2023-08-14 |
2026-04-21 |
뉴림 파머슈티칼스(1991) 리미티드 |
Gal475 조성물 및 그의 사용 방법
|
|
WO2025162971A1
(en)
|
2024-01-31 |
2025-08-07 |
Sanifit Therapeutics, S.A. |
Substituted ip5 compounds for use in the treatment, inhibition of progression, and prevention of ectopic calcification
|
|
WO2025217094A1
(en)
|
2024-04-08 |
2025-10-16 |
University Of Rochester |
Interleukin receptor-associated kinase (irak) protac degraders and medical use thereof
|
|
WO2025217096A1
(en)
|
2024-04-08 |
2025-10-16 |
University Of Rochester |
Inhibitors of leucine-rich repeat kinase 2 (lrrk2) and medical uses thereof
|
|
WO2025217379A1
(en)
|
2024-04-10 |
2025-10-16 |
University Of Rochester |
Drug treatment for macular degeneration
|
|
WO2026050206A1
(en)
|
2024-08-27 |
2026-03-05 |
Ironwood Pharmaceuticals, Inc. |
Combinations of glp-1 and guanylate cyclase c (gc-c) receptor agonists
|
|
WO2026136387A1
(en)
|
2024-12-16 |
2026-06-25 |
University Of Rochester |
Drug treatment for macular degeneration
|